Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves the antiangiogenic efficacy for advanced stage mouse corneal neovascularization

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 249, Issue 10, 2011, Pages 1493-1501

  Chaoran, Zhang ^a   Zhirong, Lin ^a   Gezhi, Xu ^a  

^a EYE AND ENT HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Corneal neovascularization; PDGF; Pericyte; Tyrosine kinase; VEGF

Indexed keywords

6,7 DIMETHOXY 2 PHENYLQUINOXALINE; ANGIOGENESIS INHIBITOR; CD31 ANTIGEN; NG2 CHONDROITIN SULFATE PROTEOGLYCAN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEOCHONDROITIN SULFATE; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR II; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORNEA EPITHELIUM; CORNEA LIMBUS; CORNEA NEOVASCULARIZATION; ENDOTHELIUM CELL; FLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; STAGING;

ANGIOGENESIS INHIBITORS; ANIMALS; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIUM, CORNEAL; LIMBUS CORNEAE; MALE; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TREATMENT OUTCOME; TYRPHOSTINS;

EID: 80755190092     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-011-1709-6     Document Type: Article

References (40)

1. RJ Epstein RD Stulting RL Hendricks DM Harris 1987 Corneal neovascularization. Pathogenesis and inhibition Cornea 6 4 250 257 2446823 10.1097/00003226-198706040-00004 1:STN:280:DyaL1c%2FotFKksg%3D%3D (Pubitemid 18005952)
2. P Lee CC Wang AP Adamis 1998 Ocular neovascularization: an epidemiologic review Surv Ophthalmol 43 3 245 269 9862312 10.1016/S0039-6257(98)00035-6 1:STN:280:DyaK1M%2FnslWhug%3D%3D (Pubitemid 28558273)
3. W Risau 1997 Mechanisms of angiogenesis Nature 386 671 674 9109485 10.1038/386671a0 1:STN:280:DyaK2s3mtlGksg%3D%3D (Pubitemid 27193480)
4. V Nehls K Denzer D Drenckhahn 1992 Pericyte involvement in capillary sprouting during angiogenesis in situ Cell Tissue Res 270 469 474 1283113 10.1007/BF00645048 1:STN:280:DyaK3s7jslaruw%3D%3D
5. E Cabebe H Wakelee 2007 Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors Curr Treat Options Oncol 8 1 15 27 17634832 10.1007/s11864-007-0022-4
6. AP Adamis DT Shima MJ Tolentino ES Gragoudas N Ferrara J Folkman PA D'Amore JW Miller 1996 Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate Arch Ophthalmol 114 66 71 8540853 1:CAS:528:DyaK28Xht1aisb0%3D (Pubitemid 26026196)
7. S Amano R Rohan M Kuroki M Tolentino AP Adamis 1998 Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization Invest Ophthalmol Vis Sci 39 18 22 9430540 1:STN:280:DyaK1c%2FptVCjtw%3D%3D (Pubitemid 28040457)
8. GS Robinson EA Pierce SL Rook E Foley R Webb LE Smith 1996 Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy Proc Natl Acad Sci USA 93 4851 4856 8643492 10.1073/pnas.93.10.4851 1:CAS:528:DyaK28XjtVKlsbY%3D (Pubitemid 26162840)
9. MG Krzystolik MA Afshari AP Adamis J Gaudreault ES Gragoudas NA Michaud W Li E Connolly CA O'Neill JW Miller 2002 Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment Arch Ophthalmol 120 338 346 11879138 1:CAS:528: DC%2BD38Xitlyqtbw%3D (Pubitemid 34250056)
10. N Singh E Higgins S Amin P Jani E Richter A Patel R Kaur J Wang J Ambati Z Dong BK Ambati 2007 Unique homologous siRNA blocks hypoxia-induced VEGF upregulation in human corneal cells and inhibits and regresses murine corneal neovascularization Cornea 26 1 65 72 17198016 10.1097/ICO.0b013e31812f6c95 (Pubitemid 47442765)
11. N Singh E Higgins S Amin P Jani E Richter A Patel R Kaur J Wang J Ambati Z Dong BK Ambati 2005 Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo Invest Ophthalmol Vis Sci 46 5 1647 1652 15851564 10.1167/iovs.04-1172 (Pubitemid 44843599)
12. LE Benjamin I Hemo E Keshet 1998 A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF Development 125 1591 1598 9521897 1:CAS:528:DyaK1cXjslemsLg%3D (Pubitemid 28256727)
13. LE Benjamin D Golijanin A Itin D Pode E Keshet 1999 Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal J Clin Invest 103 159 165 9916127 10.1172/JCI5028 1:CAS:528:DyaK1MXltFeruw%3D%3D (Pubitemid 29053133)
14. AM Joussen V Poulaki N Mitsiades SU Stechschulte B Kirchhof DA Dartt GH Fong J Rudge SJ Wiegand GD Yancopoulos AP Adamis 2003 VEGF-dependent conjunctivalization of the corneal surface Invest Ophthalmol Vis Sci 44 117 123 12506063 10.1167/iovs.01-1277 (Pubitemid 36134263)
15. AD Proia DB Chandler WL Haynes CF Smith C Suvarnamani FH Erkel GK Klintworth 1988 Quantitation of corneal neovascularization using computerized image analysis Lab Invest 58 473 479 2451768 1:STN:280:DyaL1c7ovVOjsw%3D%3D
16. Q Ebrahem SS Chaurasia A Vasanji JH Qi PA Klenotic A Cutler K Asosingh S Erzurum B Anand-Apte 2010 Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo Am J Pathol 176 1 496 503 19948826 10.2353/ajpath.2010.080642 1:CAS:528: DC%2BC3cXhs12rtbg%3D
17. MS Conners F Urbano C Vafeas RA Stoltz MW Dunn ML Schwartzman 1997 Alkali burn-induced synthesis of inflammatory eicosanoids in rabbit corneal epithelium Invest Ophthalmol Vis Sci 38 10 1963 1971 9331260 1:STN:280: DyaK2svntVyjsg%3D%3D (Pubitemid 27407515)
18. E Campos-Mollo JJ Pérez-Santonja M Lledó-Riquelme E Ortega Pastor JL Alió 2011 New corneal neovascularization model in rabbits for angiogenesis research Ophthalmic Res 45 3 135 141 20847576 10.1159/000319749
19. DH Ma JK Chen F Zhang KY Lin JY Yao JS Yu 2006 Regulation of corneal angiogenesis in limbal stem cell deficiency Prog Retin Eye Res 25 6 563 590 17079182 10.1016/j.preteyeres.2006.09.001 1:CAS:528:DC%2BD28XhtFKls7nN (Pubitemid 44666509)
20. T Alon I Hemo A Itin J Pe'er J Stone E Keshet 1995 Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity Nat Med 1 1024 1028 7489357 10.1038/nm1095-1024 1:CAS:528:DyaK2MXosVGgu7w%3D
21. EA Pierce RL Avery ED Foley LP Aiello LE Smith 1995 VEGF expression in a mouse model of retinal neovascularization Proc Natl Acad Sci USA 92 905 909 7846076 10.1073/pnas.92.3.905 1:CAS:528:DyaK2MXjsVKhsr0%3D
22. M Shibuya L Claesson-Welsh 2006 Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis Exp Cell Res 312 549 560 16336962 10.1016/j.yexcr.2005.11.012 1:CAS:528:DC%2BD28XhvVWltbo%3D (Pubitemid 43290332)
23. MS Gee WN Procopio S Makonnen MD Feldman NM Yeilding WM Lee 2003 Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy Am J Pathol 162 1883 193
24. I Helfrich I Scheffrahn S Bartling J Weis V von Felbert M Middleton M Kato S Ergün D Schadendorf 2010 Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma J Exp Med 207 3 491 503 20194633 10.1084/jem.20091846 1:CAS:528:DC%2BC3cXjvVOhsL0%3D
25. C Cursiefen C Hofmann-Rummelt M Küchle U Schlötzer-Schrehardt 2003 Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation Br J Ophthalmol 87 1 101 106 12488272 10.1136/bjo.87.1.101 1:STN:280:DC%2BD38jisFGntg%3D%3D (Pubitemid 36071788)
26. VPT Hoppenreijs E Pels GF Vrensen PC Felten WF Treffers 1993 Platelet-derived growth factor: receptor expression in corneas and effects on corneal cells Invest Ophthalmol Vis Sci 34 637 649 8449682 1:STN:280: DyaK3s7psVGisw%3D%3D (Pubitemid 23095218)
27. WJ Kim RR Mohan RR Mohan SE Wilson 1999 Effect of PDGF, IL-1alpha, and BMP2/4 on corneal fibroblast chemotaxis: expression of the platelet-derived growth factor system in the cornea Invest Ophthalmol Vis Sci. 40 7 1364 1372 10359318 1:STN:280:DyaK1M3osFymsw%3D%3D (Pubitemid 29252327)
28. A Abramsson P Lindblom C Betsholtz 2003 Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors J Clin Invest 112 8 1142 1151 14561699 1:CAS:528: DC%2BD3sXotlWis7w%3D (Pubitemid 38056291)
29. P Lindblom H Gerhardt S Liebner A Abramsson M Enge M Hellstrom G Backstrom S Fredriksson U Landegren HC Nystrom G Bergstrom E Dejana A Ostman P Lindahl C Betsholtz 2003 Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall Genes Dev 17 15 1835 1840 12897053 10.1101/gad.266803 1:CAS:528:DC%2BD3sXmt1SjtrY%3D (Pubitemid 36944561)
30. RK Jain MF Booth 2003 What brings pericytes to tumor vessels? J Clin Invest 112 8 1134 1136 14561696 1:CAS:528:DC%2BD3sXotlWisrc%3D (Pubitemid 38056288)
31. N Reinmuth W Liu YD Jung SA Ahmad RM Shaheen F Fan CD Bucana G McMahon GE Gallick LM Ellis 2001 Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival FASEB J 15 7 1239 1241 11344100 1:CAS:528:DC%2BD3MXlvVOmtL0%3D
32. G Bergers S Song 2005 The role of pericytes in blood-vessel formation and maintenance Neuro Oncol 7 4 452 464 16212810 10.1215/S1152851705000232 1:CAS:528:DC%2BD2MXht1SisLvP (Pubitemid 41555617)
33. Y Hasumi A Kłosowska-Wardega M Furuhashi A Ostman CH Heldin C Hellberg 2007 Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling Int J Cancer 121 12 2606 2614 17691110 10.1002/ijc.22999 1:CAS:528:DC%2BD2sXhtl2qsLzF (Pubitemid 350136402)
34. R Erber A Thurnher AD Katsen G Groth H Kerger HP Hammes MD Menger A Ullrich P Vajkoczy 2004 Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms FASEB J 18 2 338 340 14657001 1:CAS:528:DC%2BD2cXht1Gjtrg%3D
35. G Bergers S Song N Meyer-Morse E Bergsland D Hanahan 2003 Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors J Clin Investig 111 9 1287 1295 12727920 1:CAS:528: DC%2BD3sXjsFCrsr4%3D (Pubitemid 36554699)
36. H Uzui JD Lee H Shimizu H Tsutani T Ueda 2000 The role of protein-tyrosine phosphorylation and gelatinase production in the migration and proliferation of smooth muscle cells Atherosclerosis 149 1 51 59 10704614 10.1016/S0021-9150(99)00295-6 1:CAS:528:DC%2BD3cXhsVagurs%3D (Pubitemid 30125971)
37. B Westermark L Claesson-Welsh CH Heldin 1989 Structural and functional aspects of the receptors for platelet-derived growth factor Prog Growth Factor Res 1 4 253 266 2562360 10.1016/0955-2235(89)90014-8 1:CAS:528: DyaK3cXhslagtb8%3D
38. DA Bradley R Dunn D Nanus W Stadler R Dreicer J Rosenberg DC Smith M Hussain 2007 Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design Clin Genitourin Cancer 5 7 460 463 18272031 10.3816/CGC.2007.n.037 1:CAS:528:DC%2BD1cXitVGqs7o%3D (Pubitemid 351219702)
39. DW Kim B Lu DE Hallahan 2004 Receptor tyrosine kinase inhibitors as anti-angiogenic agents Curr Opin Investig Drugs 5 6 597 604 15242247 1:CAS:528:DC%2BD2cXnt1SrsLk%3D
40. JJ Pérez-Santonja E Campos-Mollo M Lledó-Riquelme J Javaloy JL Alió 2010 Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and sunitinib (anti-VEGF and anti-PDGF) in an animal model Am J Ophthalmol 150 519 528 20591397 10.1016/j.ajo.2010.04.024